BIOTON S.A. Logo

BIOTON S.A.

BIO.WA

(1.5)
Stock Price

3,20 PLN

-1.5% ROA

-1.14% ROE

-41.89x PER

Market Cap.

286.786.428,00 PLN

10.45% DER

0% Yield

-3.67% NPM

BIOTON S.A. Stock Analysis

BIOTON S.A. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

BIOTON S.A. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.52x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (12%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 ROE

The stock's ROE falls within an average range (0.31%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (0.42%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

5 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

6 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock appears overvalued (-996) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

BIOTON S.A. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

BIOTON S.A. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

BIOTON S.A. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

BIOTON S.A. Revenue
Year Revenue Growth
2005 151.586.000
2006 215.479.000 29.65%
2007 270.942.000 20.47%
2008 293.517.000 7.69%
2009 286.228.000 -2.55%
2010 378.595.000 24.4%
2011 288.984.000 -31.01%
2012 406.303.000 28.87%
2013 340.358.000 -19.38%
2014 377.303.000 9.79%
2015 404.408.000 6.7%
2016 277.613.000 -45.67%
2017 361.649.000 23.24%
2018 241.166.000 -49.96%
2019 202.032.000 -19.37%
2020 221.788.000 8.91%
2021 163.034.000 -36.04%
2022 233.159.000 30.08%
2023 202.808.000 -14.97%
2023 181.636.000 -11.66%
2024 202.440.000 10.28%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

BIOTON S.A. Research and Development Expenses
Year Research and Development Expenses Growth
2005 0
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 14.174.000 100%
2011 8.362.000 -69.5%
2012 6.179.000 -35.33%
2013 9.807.000 36.99%
2014 3.796.000 -158.35%
2015 3.577.000 -6.12%
2016 7.586.000 52.85%
2017 8.854.000 14.32%
2018 32.983.000 73.16%
2019 6.837.000 -382.42%
2020 3.999.000 -70.97%
2021 4.665.000 14.28%
2022 5.337.000 12.59%
2023 5.488.000 2.75%
2023 5.505.000 0.31%
2024 4.320.000 -27.43%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

BIOTON S.A. General and Administrative Expenses
Year General and Administrative Expenses Growth
2005 22.519.000
2006 40.941.000 45%
2007 59.909.000 31.66%
2008 72.695.000 17.59%
2009 123.834.000 41.3%
2010 100.458.000 -23.27%
2011 95.106.000 -5.63%
2012 78.061.000 -21.84%
2013 60.772.000 -28.45%
2014 61.764.000 1.61%
2015 64.662.000 4.48%
2016 54.037.000 -19.66%
2017 54.003.000 -0.06%
2018 50.833.000 -6.24%
2019 38.638.000 -31.56%
2020 38.751.000 0.29%
2021 27.900.000 -38.89%
2022 30.273.000 7.84%
2023 31.256.000 3.14%
2023 30.467.000 -2.59%
2024 34.524.000 11.75%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

BIOTON S.A. EBITDA
Year EBITDA Growth
2005 51.734.000
2006 134.186.000 61.45%
2007 127.877.000 -4.93%
2008 -53.531.000 338.88%
2009 -488.195.000 89.03%
2010 135.680.000 459.81%
2011 13.432.000 -910.13%
2012 82.785.000 83.77%
2013 38.259.000 -116.38%
2014 67.057.000 42.95%
2015 65.996.000 -1.61%
2016 22.673.000 -191.08%
2017 40.748.000 44.36%
2018 -13.352.000 405.18%
2019 -38.756.000 65.55%
2020 81.840.000 147.36%
2021 42.785.000 -91.28%
2022 51.964.000 17.66%
2023 15.500.000 -235.25%
2023 32.053.000 51.64%
2024 26.688.000 -20.1%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

BIOTON S.A. Gross Profit
Year Gross Profit Growth
2005 81.189.000
2006 133.837.000 39.34%
2007 148.008.000 9.57%
2008 129.147.000 -14.6%
2009 111.305.000 -16.03%
2010 212.533.000 47.63%
2011 102.586.000 -107.18%
2012 213.466.000 51.94%
2013 145.807.000 -46.4%
2014 158.298.000 7.89%
2015 167.084.000 5.26%
2016 138.023.000 -21.06%
2017 186.271.000 25.9%
2018 116.123.000 -60.41%
2019 102.164.000 -13.66%
2020 104.698.000 2.42%
2021 77.787.000 -34.6%
2022 95.750.000 18.76%
2023 57.920.000 -65.31%
2023 72.853.000 20.5%
2024 70.336.000 -3.58%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

BIOTON S.A. Net Profit
Year Net Profit Growth
2005 34.627.000
2006 92.698.000 62.65%
2007 26.572.000 -248.86%
2008 -223.033.000 111.91%
2009 -599.878.000 62.82%
2010 110.726.000 641.77%
2011 -83.936.000 231.92%
2012 37.837.000 321.84%
2013 -6.443.000 687.26%
2014 3.678.000 275.18%
2015 -522.855.000 100.7%
2016 -28.567.000 -1730.28%
2017 -7.266.000 -293.16%
2018 26.266.000 127.66%
2019 -126.693.000 120.73%
2020 33.920.000 473.51%
2021 2.882.000 -1076.96%
2022 1.421.000 -102.81%
2023 -17.660.000 108.05%
2023 2.275.000 876.26%
2024 -11.172.000 120.36%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

BIOTON S.A. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2005 2
2006 4 66.67%
2007 1 -200%
2008 -7 114.29%
2009 -14 50%
2010 2 800%
2011 -1 300%
2012 1 0%
2013 0 0%
2014 0 0%
2015 -6 100%
2016 0 0%
2017 0 0%
2018 0 0%
2019 -1 100%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

BIOTON S.A. Free Cashflow
Year Free Cashflow Growth
2005 -30.453.000
2006 -201.957.000 84.92%
2007 -196.910.000 -2.56%
2008 -159.588.000 -23.39%
2009 -183.313.000 12.94%
2010 -17.968.000 -920.22%
2011 -109.806.000 83.64%
2012 37.325.000 394.19%
2013 18.424.000 -102.59%
2014 14.036.000 -31.26%
2015 -4.533.000 409.64%
2016 -1.270.000 -256.93%
2017 -16.164.000 92.14%
2018 -15.568.000 -3.83%
2019 -6.750.000 -130.64%
2020 37.266.000 118.11%
2021 -7.370.000 605.64%
2022 26.504.000 127.81%
2023 6.153.000 -330.75%
2023 -4.541.000 235.5%
2024 6.072.000 174.79%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

BIOTON S.A. Operating Cashflow
Year Operating Cashflow Growth
2005 7.127.000
2006 -10.763.000 166.22%
2007 -530.000 -1930.75%
2008 37.745.000 101.4%
2009 -80.222.000 147.05%
2010 27.170.000 395.26%
2011 -22.200.000 222.39%
2012 144.796.000 115.33%
2013 79.963.000 -81.08%
2014 41.874.000 -90.96%
2015 24.023.000 -74.31%
2016 23.146.000 -3.79%
2017 17.503.000 -32.24%
2018 27.880.000 37.22%
2019 46.707.000 40.31%
2020 41.949.000 -11.34%
2021 5.522.000 -659.67%
2022 56.082.000 90.15%
2023 14.785.000 -279.32%
2023 39.625.000 62.69%
2024 8.672.000 -356.93%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

BIOTON S.A. Capital Expenditure
Year Capital Expenditure Growth
2005 37.580.000
2006 191.194.000 80.34%
2007 196.380.000 2.64%
2008 197.333.000 0.48%
2009 103.091.000 -91.42%
2010 45.138.000 -128.39%
2011 87.606.000 48.48%
2012 107.471.000 18.48%
2013 61.539.000 -74.64%
2014 27.838.000 -121.06%
2015 28.556.000 2.51%
2016 24.416.000 -16.96%
2017 33.667.000 27.48%
2018 43.448.000 22.51%
2019 53.457.000 18.72%
2020 4.683.000 -1041.51%
2021 12.892.000 63.68%
2022 29.578.000 56.41%
2023 8.632.000 -242.66%
2023 44.166.000 80.46%
2024 2.600.000 -1598.69%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

BIOTON S.A. Equity
Year Equity Growth
2005 255.418.000
2006 808.105.000 68.39%
2007 886.793.000 8.87%
2008 1.237.686.000 28.35%
2009 1.079.958.000 -14.61%
2010 1.169.880.000 7.69%
2011 1.384.874.000 15.52%
2012 1.336.633.000 -3.61%
2013 1.385.113.000 3.5%
2014 1.445.577.000 4.18%
2015 806.639.000 -79.21%
2016 813.825.000 0.88%
2017 773.254.000 -5.25%
2018 712.793.000 -8.48%
2019 581.999.000 -22.47%
2020 619.645.000 6.08%
2021 622.739.000 0.5%
2022 606.060.000 -2.75%
2023 606.358.000 0.05%
2023 602.956.000 -0.56%
2024 598.557.000 -0.73%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

BIOTON S.A. Assets
Year Assets Growth
2005 358.123.000
2006 991.633.000 63.89%
2007 1.546.152.000 35.86%
2008 2.064.772.000 25.12%
2009 1.604.804.000 -28.66%
2010 1.581.662.000 -1.46%
2011 2.024.549.000 21.88%
2012 1.915.324.000 -5.7%
2013 1.890.798.000 -1.3%
2014 1.953.895.000 3.23%
2015 1.250.053.000 -56.3%
2016 1.295.187.000 3.48%
2017 1.141.973.000 -13.42%
2018 1.010.026.000 -13.06%
2019 881.417.000 -14.59%
2020 867.107.000 -1.65%
2021 865.189.000 -0.22%
2022 810.326.000 -6.77%
2023 822.224.000 1.45%
2023 823.197.000 0.12%
2024 799.057.000 -3.02%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

BIOTON S.A. Liabilities
Year Liabilities Growth
2005 102.705.000
2006 183.528.000 44.04%
2007 659.359.000 72.17%
2008 827.086.000 20.28%
2009 524.846.000 -57.59%
2010 411.782.000 -27.46%
2011 639.675.000 35.63%
2012 578.691.000 -10.54%
2013 505.685.000 -14.44%
2014 508.318.000 0.52%
2015 443.414.000 -14.64%
2016 481.362.000 7.88%
2017 368.719.000 -30.55%
2018 297.233.000 -24.05%
2019 299.418.000 0.73%
2020 247.462.000 -21%
2021 242.450.000 -2.07%
2022 204.266.000 -18.69%
2023 215.866.000 5.37%
2023 220.241.000 1.99%
2024 185.736.000 -18.58%

BIOTON S.A. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
2.17
Net Income per Share
-0.08
Price to Earning Ratio
-41.89x
Price To Sales Ratio
1.54x
POCF Ratio
6.32
PFCF Ratio
22.12
Price to Book Ratio
0.48
EV to Sales
1.82
EV Over EBITDA
21.83
EV to Operating CashFlow
7.48
EV to FreeCashFlow
26.19
Earnings Yield
-0.02
FreeCashFlow Yield
0.05
Market Cap
0,29 Bil.
Enterprise Value
0,34 Bil.
Graham Number
3.54
Graham NetNet
-1.19

Income Statement Metrics

Net Income per Share
-0.08
Income Quality
-6.63
ROE
-0.01
Return On Assets
-0.01
Return On Capital Employed
0
Net Income per EBT
1.75
EBT Per Ebit
-3.76
Ebit per Revenue
0.01
Effective Tax Rate
-0.75

Margins

Sales, General, & Administrative to Revenue
0.17
Research & Developement to Revenue
0.03
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.34
Operating Profit Margin
0.01
Pretax Profit Margin
-0.02
Net Profit Margin
-0.04

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.53
Free CashFlow per Share
0.15
Capex to Operating CashFlow
0.71
Capex to Revenue
0.17
Capex to Depreciation
0.99
Return on Invested Capital
0
Return on Tangible Assets
-0.02
Days Sales Outstanding
47.44
Days Payables Outstanding
127.75
Days of Inventory on Hand
362.71
Receivables Turnover
7.69
Payables Turnover
2.86
Inventory Turnover
1.01
Capex per Share
0.38

Balance Sheet

Cash per Share
0,05
Book Value per Share
7,14
Tangible Book Value per Share
3.14
Shareholders Equity per Share
6.97
Interest Debt per Share
0.82
Debt to Equity
0.1
Debt to Assets
0.08
Net Debt to EBITDA
3.39
Current Ratio
1.04
Tangible Asset Value
0,27 Bil.
Net Current Asset Value
-0,03 Bil.
Invested Capital
656594000
Working Capital
0,01 Bil.
Intangibles to Total Assets
0.43
Average Receivables
0,02 Bil.
Average Payables
0,05 Bil.
Average Inventory
120462000
Debt to Market Cap
0.22

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

BIOTON S.A. Dividends
Year Dividends Growth

BIOTON S.A. Profile

About BIOTON S.A.

BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceuticals, pharmaceutical preparations, pharmaceutical substances, medications, and other pharmaceutical products in Poland, China, Thailand, Vietnam, Libya, Argentina, Ukraine, Malta, Yemen, and the Russian Federation. The company offers recombinant human and classic insulin; oral anti-diabetic medication products; dietary supplements; strips for measuring sugar in blood, as well as OTC preparation for diabetics; diabetics drugs insulin vials and cartridges, including Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes monitoring technology, as well as needles. It engages in advertising, advisory, and company management activities. The company was founded in 1989 and is based in Ozarów Mazowiecki, Poland.

CEO
Mr. Jeremy Launders
Employee
355
Address
ul. Poznanska 12
Ozarów Mazowiecki, 05-850

BIOTON S.A. Executives & BODs

BIOTON S.A. Executives & BODs
# Name Age
1 Mr. Jeremy Launders
Chief Executive Officer & President of the Management Board
70
2 Ms. Anna Grabowska
Senior Finance Manager
70
3 Mr. Mateusz Patryk Kosecki
Head of Biolek Business Unit & Chief Executive Officer of Biolek Sp. Z O.O.
70
4 Mr. Adam Tomasz Polonek
Member of Management Board
70
5 Mr. Michal Deptuch
Operations Director
70
6 Renata Prokopczyk
Chief Accountant
70
7 Ms. Kamila Musnicka
Director of Legal Department
70

BIOTON S.A. Competitors